☆ 4.6 Review

Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Alfredo Addeo et al.

Summary: Precision oncology informed by genomic information has made significant progress in the last decade. Multiple targetable genomic alterations have been identified in various cancer types, including a 2% occurrence of RET alterations. The rapid development and approval of selective RET inhibitors have opened up new possibilities for RET precision oncology.

PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Immunology

Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma

Danfeng Weng et al.

Summary: This study explores the exclusive gene profile of MTC and constructs a comprehensive regulatory network to uncover potential key biomarkers. Results identified 81 upregulated genes and 22 downregulated genes in MTC. The constructed regulatory network is related to immune characteristics and patient survival, and plays an important role in MTC immune score, immune cell infiltration, and immunotherapeutic molecules.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Surgery

Medullary thyroid cancer with RET V804M mutation: more indolent than expected?

Nicholas A. Frisco et al.

Summary: A study was conducted on patients with a RET V804M mutation, finding that most patients had indolent disease without classic multiple endocrine neoplasia type 2A features. A calcitonin level >5 pg/mL may be meaningful for surveillance and timing of surgery.

SURGERY (2023)

Add to Collection

Review Oncology

The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading

C. Christofer Juhlin et al.

Summary: The World Health Organization has released the fifth edition of the Classification of Endocrine and Neuroendocrine Tumors. This publication includes changes to the nomenclature of thyroid diseases and introduces novel concepts important for patient management. The classification now groups non-neoplastic and benign neoplastic lesions under 'thyroid follicular nodular disease', reflecting their clonal and non-clonal proliferations in multinodular goiter. Thyroid neoplasms originating from follicular cells are categorized into benign, low-risk, and malignant neoplasms, emphasizing the subtyping of papillary thyroid carcinoma based on histomorphologic features and redefining the cribriform-morular variant as cribriform-morular thyroid carcinoma. The review highlights the key changes in the fifth edition and their impact on patient management and future directions in this field.

ENDOCRINE-RELATED CANCER (2023)

Add to Collection

Article Oncology

Molecular targets of tyrosine kinase inhibitors in thyroid cancer

Poupak Fallahi et al.

Summary: Thyroid cancer is a common cancer with a rising incidence worldwide. Surgery is the primary treatment strategy, but some patients experience recurrence during follow-up. Resistance to radioactive iodine is a poor prognostic factor. Significant advances have been made in understanding the molecular pathways of thyroid cancer, leading to the development of tyrosine kinase inhibitors as new treatment options. However, further research is needed.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial

Vatche Tchekmedyian et al.

Summary: This study aimed to restore radioiodine avidity in patients with BRAF-mutant radioiodine refractory thyroid cancer by combined inhibition of BRAF and HER3 using vemurafenib and CDX-3379, providing preliminary evidence of the safety and efficacy of this treatment approach.

THYROID (2022)

Add to Collection

Article Oncology

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer The REALITY Randomized Clinical Trial

Yansong Lin et al.

Summary: The study aimed to assess the efficacy and safety of apatinib in patients with progressive locally advanced or metastatic RAIR-DTC. Results showed that apatinib demonstrated significant clinical benefits in terms of prolonged PFS and improved overall survival with manageable safety profile.

JAMA ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer

S. Filetti et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies

Maria San Roman-Gil et al.

Summary: Thyroid cancer is a common endocrine malignancy with increasing incidence. Recent advances in understanding the molecular mechanisms of thyroid cancer have improved treatment approaches. Selective RET inhibitors have shown promising results in selected patients, but resistance mechanisms have been observed. This review provides an analysis of resistance mechanisms to RET inhibitors, aiming to inform the development of next-generation therapies and combination strategies.

CANCER TREATMENT REVIEWS (2022)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Steven G. Waguespack et al.

Summary: This study evaluated the efficacy and safety of Larotrectinib in patients with TRK fusion-positive thyroid carcinoma. The results showed that Larotrectinib demonstrated rapid and durable disease control and a favorable safety profile in these patients, making it a potential treatment option for advanced thyroid carcinoma.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Ezra Y. Rosen et al.

Summary: The study has established the efficacy of the highly selective RET inhibitor selpercatinib in patients with RET-driven cancers, but also discovered potential mechanisms of resistance, revealing the complexity of acquired resistance and suggesting the importance of combination therapy targeting alternative pathways in overcoming resistance.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Endocrinology & Metabolism

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine

Antonio Matrone et al.

Summary: Medullary thyroid carcinoma (MTC) is a neuroendocrine malignant tumor originating from parafollicular C-cells. Surgical treatments, multikinase inhibitors, highly selective RET inhibitors, and radionuclide therapy are discussed as systemic treatments for advanced and metastatic MTC.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Oncology

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Elizabeth S. Duke et al.

Summary: On September 17, 2021, the FDA approved cabozantinib for the treatment of RAI-refractory locally advanced or metastatic differentiated thyroid cancer. The approval was based on data from an international trial, which showed that cabozantinib significantly prolonged progression-free survival compared to placebo.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Immunology

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review

Jiayi Li et al.

Summary: This case report presented a 43-year-old male patient with RAIR DTC who showed disease control and partial response to combination immunotherapy of apatinib plus camrelizumab after resistance to first-line therapy. Long-term mild efficacy was observed with occasional diarrhea as the main adverse event.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis

Youwen Zhu et al.

Summary: The study revealed that apatinib was more cost-effective compared to lenvatinib in the first-line treatment of Chinese patients with RAIR-DTC, as indicated by network meta-analysis and cost-effectiveness analysis results.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Oncology

Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)

Takuya Higashiyama et al.

Summary: The study assessed the efficacy and safety of lenvatinib in patients with unresectable anaplastic thyroid cancer (ATC), revealing a low overall survival rate and a limited number of responders. However, responses were durable, suggesting potential benefits for selected patients.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Endocrinology & Metabolism

Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives

Katerina Saltiki et al.

Summary: In recent years, research on the molecular biology and RET-activating mutations in medullary thyroid carcinoma (MTC) has led to the development of novel targeted therapies. While several drugs have been approved for MTC treatment, drug resistance remains a major challenge. Therefore, understanding the molecular mechanisms of tumorigenesis and drug resistance is crucial for the development of more effective therapies for MTC.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Add to Collection

Review Oncology

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective

Alice Nervo et al.

Summary: For patients with advanced thyroid cancer who are resistant to radioactive iodine therapy, a multidisciplinary and personalized approach is essential, including options such as local treatments, systemic therapies, and targeted therapies tailored to individual cases. Next-generation sequencing assays have revolutionized the management of thyroid cancer by identifying genetic alterations, with novel selective targeted therapies and immune checkpoint inhibitors showing promising results.

CANCER MANAGEMENT AND RESEARCH (2022)

Add to Collection

Review Oncology

RET kinase inhibitors for RET-altered thyroid cancers

Danica M. Vodopivec et al.

Summary: Precision oncology has revolutionized cancer treatment by targeting specific cellular pathways. In thyroid cancer, RET gene mutations are implicated in tumorigenesis. Current drugs targeting RET tyrosine kinase receptor lack specificity and can lead to drug resistance. Highly selective first-generation RET inhibitors show promising results, but the development of second-generation RET inhibitors is necessary to combat emerging mutations.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Ezra Y. Rosen et al.

Summary: The RET proto-oncogene is activated by gene fusion in 1%-2% of NSCLC, while MET amplification is associated with resistance to selpercatinib. Combination therapy with selpercatinib and crizotinib can overcome MET-mediated resistance to RET inhibition.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Endocrinology & Metabolism

Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial

Yan-Song Lin et al.

Summary: The study evaluated the efficacy and safety of the new multikinase inhibitor donafenib in treating locally advanced or metastatic RAIR-DTC. Both 200mg and 300mg doses of donafenib showed similar efficacy in terms of objective response rate, with the 300mg dose demonstrating a trend towards longer progression-free survival and more tumor shrinkage. The most common grade 3 treatment-related adverse events were palmar-plantar erythrodysesthesia and hypertension.

THYROID (2021)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Non-coding RNA in thyroid cancer - Functions and mechanisms

Jun Cao et al.

Summary: Thyroid cancer is the most common endocrine malignant tumor, with significantly increased incidence in recent years. Abnormal expression patterns of noncoding RNAs have been found in human thyroid cancer. Short ncRNAs, particularly miRNAs, have been extensively studied, while long ncRNAs, especially in human cancers like thyroid cancer, lack sufficient research.

CANCER LETTERS (2021)

Add to Collection

Article Oncology

Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR

Christelle de la Fouchardiere et al.

Summary: The study investigated the efficacy of intermittent versus continuous pazopanib administration in RAIR-TC patients, showing no significant difference in efficacy or tolerance between the two treatment approaches.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Endocrinology & Metabolism

Current practice in patients with differentiated thyroid cancer

Martin Schlumberger et al.

Summary: Considerable changes have occurred in the management of differentiated thyroid cancer (DTC) over the past four decades, with improved diagnostic tools and prognostic classifications available. Low-risk patients make up the majority with good outcomes, while high-risk patients require more aggressive treatment and follow-up due to frequent recurrences.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Multikinase inhibitors in thyroid cancer: timing of targeted therapy

Matti L. Gild et al.

Summary: This review summarizes the evidence from clinical trials on the efficacy of tyrosine kinase inhibitors in treating thyroid cancer. It also discusses the experience with these drugs in clinical practice and factors that can help clinicians decide when to start or continue tyrosine kinase inhibitor therapy.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

Christine Dierks et al.

Summary: The combination therapy of lenvatinib and pembrolizumab may be safe and effective in patients with ATC/PDTC, resulting in complete and long-term remissions.

THYROID (2021)

Add to Collection

Article Oncology

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Dapeng Li et al.

Summary: Anlotinib demonstrated significant improvement in progression-free survival and objective response rate in patients with MTC, with a higher incidence of treatment-related adverse events. However, it showed relatively reliable safety profile in this population.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

DNA Methylation Age Drift Is Associated with Poor Outcomes and De-Differentiation in Papillary and Follicular Thyroid Carcinomas

Tiantian Liu et al.

Summary: The study reveals the presence of highly drifted DNAm age (HDDA) in cancer tissues, especially in thyroid carcinomas, with HDDA significantly associated with tumor cell dedifferentiation and poor patient outcomes. HDDA may serve as a new prognostic factor for thyroid carcinomas.

CANCERS (2021)

Add to Collection

Article Endocrinology & Metabolism

Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer

Yan-Song Lin et al.

Summary: The long-term evaluation of apatinib in patients with radioiodine refractory differentiated thyroid cancer showed sustainable efficacy and tolerable safety profile, especially for patients with BRAF(V600E) mutation.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Oncology

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

Lori J. Wirth et al.

Summary: The study aimed to evaluate the efficacy of Lenvatinib in anaplastic thyroid cancer (ATC) and found that Lenvatinib monotherapy may not be an effective treatment for ATC, suggesting the need for further investigation.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Endocrine toxicities of immune checkpoint inhibitors

Jordan J. Wright et al.

Summary: Immune checkpoint inhibitors (ICIs) have become a cornerstone of cancer therapeutics, but can also cause toxicities in various organs known as immune-related adverse events. ICIs can lead to endocrinopathies involving the thyroid, pituitary, adrenal glands, and pancreas, which are common and sometimes fatal.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?

Sergio Di Molfetta et al.

Summary: Medullary thyroid carcinoma is a rare neuroendocrine neoplasm that usually requires surgery for treatment. Recent interest in immune checkpoint inhibitors has sparked hope for new treatment options for patients with this type of cancer.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Xiangqian Zheng et al.

Summary: In Chinese patients with radioiodine-refractory differentiated thyroid cancer, treatment with lenvatinib at a starting dose of 24 mg/day significantly improved progression-free survival and objective response rate compared to placebo, with no new or unexpected toxicities observed. These results are consistent with those from the multinational phase III SELECT study involving patients with RR-DTC.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Marcia S. Brose et al.

Summary: Patients with radioiodine-refractory differentiated thyroid cancer who have previously undergone VEGFR-targeted therapy and have no available standard of care were evaluated in this study for the tyrosine kinase inhibitor cabozantinib. Results showed that cabozantinib significantly prolonged progression-free survival, potentially offering a new treatment option for these patients.

LANCET ONCOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah et al.

Summary: Pralsetinib is a new, well-tolerated, potent once-daily oral treatment option for patients with RET-altered thyroid cancer, showing significant antitumor activity and good safety profile in patients with different types of RET alterations.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS

Ji Min Oh et al.

Summary: Advanced, metastatic differentiated thyroid cancers often have a poor prognosis due to decreased NIS expression and RAI refractoriness caused by genetic aberrations such as BRAF, RAS, and RET/PTC rearrangements. These genetic abnormalities activate MAPK and PI3K/AKT signaling pathways leading to dedifferentiation of DTCs. Research in recent years has focused on strategies to restore NIS expression and RAI uptake.

THERANOSTICS (2021)

Add to Collection

Article Health Care Sciences & Services

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation

Nigel Fleeman et al.

HEALTH TECHNOLOGY ASSESSMENT (2020)

Add to Collection

Review Endocrinology & Metabolism

The Year in Medical Thyroidology Review: Current Challenges and Future Directions

Naifa Lamki Busaidy

THYROID (2020)

Add to Collection

Article Endocrinology & Metabolism

Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial

Jiaying Chen et al.

THYROID (2020)

Add to Collection

Article Oncology

Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019

Anastasios Maniakas et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

Michael C. Kreissl et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

L. J. Wirth et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers

Lara A. Dunn et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)

Add to Collection

Article Oncology

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer

Janice M. Mehnert et al.

BMC CANCER (2019)

Add to Collection

Review Health Care Sciences & Services

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model

Paul Tappenden et al.

HEALTH TECHNOLOGY ASSESSMENT (2019)

Add to Collection

Review Endocrinology & Metabolism

Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects

Tihana Ibrahimpasic et al.

THYROID (2019)

Add to Collection

Article Endocrinology & Metabolism

DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions

Mateus Camargo Barros-Filho et al.

THYROID (2019)

Add to Collection

Article Endocrinology & Metabolism

Leukocyte Mitochondrial DNA Copy Number and Risk of Thyroid Cancer: A Two-Stage Case-Control Study

Jian Zheng et al.

FRONTIERS IN ENDOCRINOLOGY (2019)

Add to Collection

Review Endocrinology & Metabolism

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond

Maria E. Cabanillas et al.

ENDOCRINE REVIEWS (2019)

Add to Collection

Review Biochemistry & Molecular Biology

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition

Gilda Varricchi et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Oncology

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S. Filetti et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer

Shunji Takahashi et al.

FUTURE ONCOLOGY (2019)

Add to Collection

Article Oncology

Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer

Viswanath Gunda et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Article Multidisciplinary Sciences

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

Raffaele Ciampi et al.

ISCIENCE (2019)

Add to Collection

Article Oncology

Selective RET kinase inhibition for patients with RET-altered cancers

V. Subbiah et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Vivek Subbiah et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Qinlian Jiao et al.

MOLECULAR CANCER (2018)

Add to Collection

Article Oncology

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

Vivek Subbiah et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Oncology

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Priyanka C. Iyer et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Review Endocrinology & Metabolism

Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications

Douglas Van Nostrand

THYROID (2018)

Add to Collection

Article Oncology

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

Viswanath Gunda et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Pharmacology & Pharmacy

The safety of apatinib for the treatment of gastric cancer

Ruixuan Geng et al.

EXPERT OPINION ON DRUG SAFETY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Therapeutic advances in anaplastic thyroid cancer: a current perspective

Shikha Saini et al.

MOLECULAR CANCER (2018)

Add to Collection

Article Oncology

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

Maria E. Cabanillas et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Lenvatinib for Anaplastic Thyroid Cancer

Makoto Tahara et al.

FRONTIERS IN ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer

M. Zou et al.

ONCOGENE (2016)

Add to Collection

Article Endocrinology & Metabolism

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer

Jill J. Bastman et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)

Add to Collection

Article Oncology

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Marcia S. Brose et al.

LANCET ONCOLOGY (2016)

Add to Collection

Review Physiology

NON-CODING RNAs IN DEVELOPMENT AND DISEASE: BACKGROUND, MECHANISMS, AND THERAPEUTIC APPROACHES

Julia Beermann et al.

PHYSIOLOGICAL REVIEWS (2016)

Add to Collection

Article Multidisciplinary Sciences

Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer

Yanlan Liu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Add to Collection

Article Endocrinology & Metabolism

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Bryan R. Haugen et al.

THYROID (2016)

Add to Collection

Letter Oncology

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response

S. Michael Rothenberg et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Review Oncology

RAS proto-oncogene in medullary thyroid carcinoma

Margarida M. Moura et al.

ENDOCRINE-RELATED CANCER (2015)

Add to Collection

Article Oncology

An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer

Sun Min Lim et al.

EUROPEAN JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib

S. Michael Rothenberg et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Review Medicine, Research & Experimental

Thyroid Cancer

Tobias Carling et al.

ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal et al.

CELL (2014)

Add to Collection

Article Endocrinology & Metabolism

Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) Enhancer (NDE) Is Associated With Reduced NIS Expression in Thyroid Tumors

Ana Luiza Galrao et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)

Add to Collection

Article Medicine, General & Internal

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose et al.

LANCET (2014)

Add to Collection

Article Endocrinology & Metabolism

MUC1 Expression in Papillary Thyroid Carcinoma Is Associated with BRAF Mutation and Lymph Node Metastasis; the Latter is the Most Important Risk Factor of Relapse

Florence Renaud et al.

THYROID (2014)

Add to Collection

Editorial Material Endocrinology & Metabolism

Definition and management of radioactive iodine-refractory differentiated thyroid cancer

Martin Schlumberger et al.

LANCET DIABETES & ENDOCRINOLOGY (2014)

Add to Collection

Article Oncology

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Endocrinology & Metabolism

Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid

Panayiotis Savvides et al.

THYROID (2013)

Add to Collection

Review Oncology

Molecular pathogenesis and mechanisms of thyroid cancer

Mingzhao Xing

NATURE REVIEWS CANCER (2013)

Add to Collection

Article Oncology

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Review Endocrinology & Metabolism

Molecular genetics and diagnosis of thyroid cancer

Yuri E. Nikiforov et al.

NATURE REVIEWS ENDOCRINOLOGY (2011)

Add to Collection

Article Oncology

IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer

Zhi Liu et al.

CLINICAL CANCER RESEARCH (2010)

Add to Collection

Article Endocrinology & Metabolism

Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma

Clarissa Capp et al.

THYROID (2010)

Add to Collection

Article Oncology

Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1

Julio C. Ricarte-Filho et al.

CANCER RESEARCH (2009)

Add to Collection

Article Oncology

Association of PTEN Gene Methylation With Genetic Alterations in the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway in Thyroid Tumors

Peng Hou et al.

CANCER (2008)

Add to Collection

Article Oncology

Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma

Jia-Jing Lee et al.

ENDOCRINE-RELATED CANCER (2008)

Add to Collection

Article Endocrinology & Metabolism

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers

Zhi Liu et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)

Add to Collection

Review Oncology

Enhancement of sodium/iodide symporter expression in thyroid and breast cancer

T. Kogai et al.

ENDOCRINE-RELATED CANCER (2006)

Add to Collection

Review Oncology

BRAF mutation in thyroid cancer

M Xing

ENDOCRINE-RELATED CANCER (2005)

Add to Collection

Review Endocrinology & Metabolism

RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors

MA Kouvaraki et al.

THYROID (2005)

Add to Collection

Article Endocrinology & Metabolism

Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors

T Dwight et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.